AR101312A1 - Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton - Google Patents
Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de brutonInfo
- Publication number
- AR101312A1 AR101312A1 ARP150102366A ARP150102366A AR101312A1 AR 101312 A1 AR101312 A1 AR 101312A1 AR P150102366 A ARP150102366 A AR P150102366A AR P150102366 A ARP150102366 A AR P150102366A AR 101312 A1 AR101312 A1 AR 101312A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- bet
- combination
- inhibitor
- bruton
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y composiciones para tratar una neoplasia de células B, que comprenden administrar una combinación de un inhibidor de BTK (ibrutinib) y un inhibidor BET. Métodos y composiciones para tratar una neoplasia de células B resistentes a BTK o una neoplasia de células B dirigida por MYC, que comprenden administrar una combinación de un inhibidor de BTK (ibrutinib) y un inhibidor de BET. Métodos para evaluar un paciente que tiene una neoplasia de células B, para el tratamiento con una combinación de un inhibidor de BTK (ibrutinib) y un inhibidor de BET basado en el nivel de expresión de MYC del paciente. Reivindicación 4: El método de conformidad con cualquier reivindicación 1 - 3, caracterizado porque el inhibidor de BET comprende CPI-0610, DUAL946, GSK525762, I-BET151, JQ1, OTX015, PFI-1, RVX-208, RVX2135, TEN-010, o una combinación de estos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462029346P | 2014-07-25 | 2014-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101312A1 true AR101312A1 (es) | 2016-12-07 |
Family
ID=55163800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102366A AR101312A1 (es) | 2014-07-25 | 2015-07-24 | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton |
Country Status (4)
Country | Link |
---|---|
US (1) | US20160022684A1 (es) |
AR (1) | AR101312A1 (es) |
TW (1) | TW201605455A (es) |
WO (1) | WO2016014859A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK) |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
RS62874B1 (sr) | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
KR20210095721A (ko) * | 2016-07-29 | 2021-08-02 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
AU2017351638A1 (en) | 2016-10-26 | 2019-06-13 | Genea Biocells USA (Holdings), Inc. | Improved generation of muscle lineage cells and therapeutic uses thereof |
HUE058289T2 (hu) | 2016-10-27 | 2022-07-28 | Celgene Quanticel Res Inc | Brómdomén és extraterminális protein inhibitor kombinációs terápia |
US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
JP7125952B2 (ja) * | 2017-05-18 | 2022-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腫瘍を治療するための薬剤の製造におけるbtk阻害剤との組み合わせでのezh2阻害剤の使用 |
CN107823645B (zh) * | 2017-11-13 | 2020-11-10 | 上海交通大学医学院附属新华医院 | BET抑制剂联合NF-κB抑制剂治疗结直肠癌及药物组合物 |
JP2021521219A (ja) * | 2018-04-18 | 2021-08-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Bet阻害剤およびプロテアソーム阻害剤を用いる併用療法 |
EP3787751A1 (en) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
US11931352B2 (en) | 2018-05-24 | 2024-03-19 | University Of Virginia Patent Foundation | Combination therapies for treating cancer |
CN111053777A (zh) * | 2018-10-16 | 2020-04-24 | 正大天晴药业集团股份有限公司 | 伊布替尼的药物组合物及其应用 |
US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
CN117320704A (zh) * | 2021-05-03 | 2023-12-29 | 蓝腾制药公司 | 血癌的治疗方法 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008069881A2 (en) * | 2006-11-06 | 2008-06-12 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
MX361772B (es) * | 2011-10-19 | 2018-12-17 | Pharmacyclics Llc | Uso de inhibidores de la tirosina cinasa de bruton (btk). |
-
2015
- 2015-07-23 US US14/807,680 patent/US20160022684A1/en not_active Abandoned
- 2015-07-23 WO PCT/US2015/041841 patent/WO2016014859A1/en active Application Filing
- 2015-07-24 TW TW104124155A patent/TW201605455A/zh unknown
- 2015-07-24 AR ARP150102366A patent/AR101312A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201605455A (zh) | 2016-02-16 |
US20160022684A1 (en) | 2016-01-28 |
WO2016014859A1 (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
CL2017003006A1 (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
CL2017003005A1 (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
CL2016002971A1 (es) | Combinación. | |
SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
DOP2016000291A (es) | Composiciones y métodos para modular la expresión del factor b del complemento | |
CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
MA40364A (fr) | Polythérapie pour le traitement du cancer | |
BR112015027477A8 (pt) | bolus, seus usos, e kit | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
CO2017002356A2 (es) | Métodos para tratar la depresión usando moduladores de nmda | |
BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
TW201613628A (en) | Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders | |
AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
MX2020003270A (es) | Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |